Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
Company profile
Ticker
AMLX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Amylyx Pharmaceuticals Canada Inc. • Amylyx Pharmaceuticals EMEA B.V. • Amylyx Pharmaceuticals Distribution Ltd. • Amylyx Pharmaceuticals Germany GmbH • Amylyx Pharmaceuticals France SAS • Amylyx Pharmaceuticals Belgium SRL • Amylyx Pharmaceuticals UK Ltd. • Amylyx Pharmaceuticals Japan K.K. ...
IRS number
464600503
AMLX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX
8 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
UPLOAD
Letter from SEC
20 Dec 23
CORRESP
Correspondence with SEC
19 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm |
Cash burn (monthly) | 37.50 mm | (no burn) | (no burn) | 19.00 k | 1.72 mm | 4.28 mm |
Cash used (since last report) | 224.10 mm | n/a | n/a | 113.54 k | 10.30 mm | 25.56 mm |
Cash remaining | -88.12 mm | n/a | n/a | 135.86 mm | 125.68 mm | 110.42 mm |
Runway (months of cash) | -2.3 | n/a | n/a | 7150.7 | 72.9 | 25.8 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 37 |
Closed positions | 17 |
Increased positions | 68 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 1.08 tn |
Total shares | 61.25 mm |
Total puts | 856.90 k |
Total calls | 954.37 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 5.05 mm | $92.47 bn |
BLK Blackrock | 3.58 mm | $65.47 bn |
Viking Global Investors | 2.96 mm | $54.24 bn |
Perceptive Advisors | 2.69 mm | $49.23 bn |
Stonepine Capital Management | 2.52 mm | $46.07 bn |
Morningside Venture Investments | 2.31 mm | $43.30 mm |
Millennium Management | 2.12 mm | $38.81 bn |
Boxer Capital | 2.08 mm | $38.16 bn |
Avidity Partners Management | 1.76 mm | $32.17 bn |
Adage Capital Partners GP, L.L.C. | 1.70 mm | $31.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Bernhardt G Zeiher | Stock Option Common Stock | Grant | Acquire A | No | No | 3.17 | 50,000 | 158.50 k | 50,000 |
26 Feb 24 | James M Frates | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 152,035 |
26 Feb 24 | James M Frates | Stock Option Common Stock | Grant | Acquire A | No | No | 17.56 | 60,000 | 1.05 mm | 60,000 |
26 Feb 24 | Joshua B Cohen | Common Stock | Grant | Acquire A | No | No | 0 | 126,667 | 0.00 | 3,027,137 |
26 Feb 24 | Joshua B Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 17.56 | 190,000 | 3.34 mm | 190,000 |
26 Feb 24 | Justin B. Klee | Common Stock | Grant | Acquire A | No | No | 0 | 126,667 | 0.00 | 2,963,443 |
26 Feb 24 | Justin B. Klee | Stock Option Common Stock | Grant | Acquire A | No | No | 17.56 | 190,000 | 3.34 mm | 190,000 |
News
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
19 Mar 24
HC Wainwright & Co. Maintains Buy on Amylyx Pharma, Lowers Price Target to $8
12 Mar 24
Goldman Sachs Downgrades Amylyx Pharma to Neutral, Lowers Price Target to $4
11 Mar 24
Leerink Partners Downgrades Amylyx Pharma to Market Perform
11 Mar 24
Baird Downgrades Amylyx Pharma to Neutral, Lowers Price Target to $4
11 Mar 24
Press releases
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
28 Mar 24
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
28 Mar 24
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline
28 Mar 24
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
27 Mar 24
ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
27 Mar 24